Virtual reality (VR) can identify early Alzheimer’s disease more accurately than ‘gold standard’ cognitive tests currently in use, suggests new research from the University of Cambridge.
The study highlights the potential of new technologies to help diagnose and monitor conditions such as Alzheimer’s disease, which affects more than 525,000 people in the UK.
In 2014, Professor John O’Keefe of UCL was jointly awarded the Nobel Prize in Physiology or Medicine for ‘discoveries of cells that constitute a positioning system in the brain’. Essentially, this means that the brain contains a mental ‘satnav’ of where we are, where we have been, and how to find our way around.
A key component of this internal satnav is a region of the brain known as the entorhinal cortex. This is one of the first regions to be damaged in Alzheimer’s disease, which may explain why ‘getting lost’ is one of the first symptoms of the disease. However, the pen-and-paper cognitive tests used in clinic to diagnose the condition are unable to test for navigation difficulties.
In collaboration with Professor Neil Burgess at UCL, a team of scientists at the Department of Clinical Neurosciences at the University of Cambridge led by Dr Dennis Chan, previously Professor O’Keefe’s PhD student, developed and trialled a VR navigation test in patients at risk of developing dementia. The results of their study are published today in the journal Brain.
In the test, a patient dons a VR headset and undertakes a test of navigation while walking within a simulated environment. Successful completion of the task requires intact functioning of the entorhinal cortex, so Dr Chan’s team hypothesised that patients with early Alzheimer’s disease would be disproportionately affected on the test.
The team recruited 45 patients with mild cognitive impairment (MCI) from the Cambridge University Hospitals NHS Trust Mild Cognitive Impairment and Memory Clinics. Patients with MCI typically exhibit memory impairment, but while MCI can indicate early Alzheimer’s, it can also be caused by other conditions such as anxiety and even normal aging. As such, establishing the cause of MCI is crucial for determining whether affected individuals are at risk of developing dementia in the future.
The researchers took samples of cerebrospinal fluid (CSF) to look for biomarkers of underlying Alzheimer’s disease in their MCI patients, with 12 testing positive. The researchers also recruited 41 age-matched healthy controls for comparison.
All of the patients with MCI performed worse on the navigation task than the healthy controls. However, the study yielded two crucial additional observations. First, MCI patients with positive CSF markers – indicating the presence of Alzheimer’s disease, thus placing them at risk of developing dementia – performed worse than those with negative CSF markers at low risk of future dementia.
Secondly, the VR navigation task was better at differentiating between these low and high risk MCI patients than a battery of currently-used tests considered to be gold standard for the diagnosis of early Alzheimer’s.
“These results suggest a VR test of navigation may be better at identifying early Alzheimer’s disease than tests we use at present in clinic and in research studies,” says Dr Chan.
VR could also help clinical trials of future drugs aimed at slowing down, or even halting, progression of Alzheimer’s disease. Currently, the first stage of drug trials involves testing in animals, typically mouse models of the disease. To determine whether treatments are effective, scientists study their effect on navigation using tests such as a water maze, where mice have to learn the location of hidden platforms beneath the surface of opaque pools of water. If new drugs are found to improve memory on this task, they proceed to trials in human subjects, but using word and picture memory tests. This lack of comparability of memory tests between animal models and human participants represents a major problem for current clinical trials.
“The brain cells underpinning navigation are similar in rodents and humans, so testing navigation may allow us to overcome this roadblock in Alzheimer’s drug trials and help translate basic science discoveries into clinical use,” says Dr Chan. “We’ve wanted to do this for years, but it’s only now that VR technology has evolved to the point that we can readily undertake this research in patients.”
In fact, Dr Chan believes technology could play a crucial role in diagnosing and monitoring Alzheimer’s disease. He is working with Professor Cecilia Mascolo at Cambridge’s Centre for Mobile, Wearable Systems and Augmented Intelligence to develop apps for detecting the disease and monitoring its progression. These apps would run on smartphones and smartwatches. As well as looking for changes in how we navigate, the apps will track changes in other everyday activities such as sleep and communication.
“We know that Alzheimer’s affects the brain long before symptoms become apparent,” says Dr Chan. “We’re getting to the point where everyday tech can be used to spot the warning signs of the disease well before we become aware of them.
“We live in a world where mobile devices are almost ubiquitous, and so app-based approaches have the potential to diagnose Alzheimer’s disease at minimal extra cost and at a scale way beyond that of brain scanning and other current diagnostic approaches.”
The Latest on: App-based diagnostics
via Google News
The Latest on: App-based diagnostics
- $124 Billion Automotive Usage Based Insurance Markets: Pay-As-You-Drive and Pay-How-You-Drive - Global Forecast to 2027 - ResearchAndMarkets.comon November 25, 2020 at 8:14 am
Dongles Segment is Expected to Dominate the Automotive Usage Based Insurance Market in 2027. The market is estimated to reach US$ 124.02 billion by 2027 from US$ US$ 19.64 billion ...
- Self-Care Intervention May Only Temporize HF Patients Discharged From EDon November 19, 2020 at 7:37 am
Extra self-care education and outpatient check-ins weren't enough to prevent events for long among heart failure (HF) patients who visited the emergency department (ED) without hospitalization, a ...
- Automobili Pininfarina, Deutsche Telekom partner for e-SIM-based connected car techon November 18, 2020 at 9:23 pm
Smart Diagnostics technology with engineering teams ... app will keep owners connected to their car at all times. App-based functions will include remotely locking and unlocking the vehicle ...
- Quick cough tests reliably ID asymptomatic COVID-19, other conditionson November 10, 2020 at 4:18 pm
As cases skyrocket and more questions arise about the high rate of false negatives returned by rapid testing in COVID-19 cases, a simple, new diagnostic test offers ... The team is developing an app ...
- Numi Now Offering At-Home Flu Shots and COVID Testson November 10, 2020 at 2:01 pm
The company has deployed the first app-based technology in Canada to offer convenient and safe mobile medical tests and services. CALGARY, Alberta, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Numi Health Inc. ( ...
- 3 Coronavirus Stocks With Long-Term Growth Potentialon November 8, 2020 at 7:06 am
If Abbott can expand its app-based tracking of test results while continuing to offer progressively cheaper, faster, and lower-friction diagnostics, it's hard to see how it the $201 billion market ...
- An Update on FDA’s Contribution to COVID-19 Diagnostic Testingon November 5, 2020 at 7:15 am
Back in the early days of the COVID-19 pandemic, we published a post outlining the different kinds of diagnostic tests that were being marketed and the different roles of the two main federal ...
- Healcerion Receives FDA Clearance for New SONON 300L Wireless, App-based Ultrasound Systemon November 2, 2020 at 4:00 pm
Healcerion, based in South Korea, was the first company to receive FDA clearance for their wireless, app-based ultrasound system back in 2015. The groundbreaking work done by South Korean ...
- Digital health news briefson October 21, 2020 at 5:00 pm
Joining the lineup in 2021 will be: Wildflower Health's app-based women's health offering ... an early-stage investment program called StarFinder Lab. Focused on novel diagnostic technologies, in ...
- STANLEY Products & Solutions upgrades access control system at Blackpool Coastal Housingon November 8, 2018 at 1:21 am
Remote diagnostics, technical issues and servicing can be carried out, and it’s also possible to remotely view status, set and unset a system and access an event log. For instance, if someone loses a ...
via Bing News